Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

A phase 2 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 124 participants.

Also called NCT03097107

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 124 participants (planned count) (from the registry)
Sponsor
Zydus Therapeutics Inc. (from the registry)
Registry
  • NCT NCT03097107
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT03097107. Randomized; quadruple masking; primary purpose treatment. Start 2017-04-06 (actual); primary completion 2023-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Condition
Dyslipidemias
Intervention (Drug)
Saroglitazar Magnesium 1 mg
Intervention (Drug)
Saroglitazar Magnesium 2 mg
Intervention (Drug)
Saroglitazar Magnesium 4 mg
Intervention (Drug)
Placebo
Lead sponsor
Zydus Therapeutics Inc. (class: industry)

Record details

Record id
cardio:ct-nct03097107
Content hash
971e71e40c00a7d6270f3118b94eb2b3839e1e5f22b58293f4766474b8e27fcd